Please login to the form below

Not currently logged in
Email:
Password:

Janssen’s Leisha Daly appointed VP of IPHA

Joins Irish trade body for pharma as plan to cut country’s drug prices agreed

Leisha Daly, IPHAThe Irish Pharmaceutical Healthcare Association (IPHA) has appointed Janssen's Dr Leisha Daly as vice president.

Dr Daly, who serves as country director at Janssen, joins the trade body at a crucial time for the pharma industry in Ireland, with the IPHA this week agreeing plans with the Department of Health and Health Service Executive (HSE) to cut the price of hundreds of medicines by an average of 10 per cent.

She takes over from Pfizer's David Gallagher as vice president, following his two years in the position, and will serve alongside fellow vice president Dr Neil Boyle of MSD.

In addition to her role at Janssen, Dr Daly has served on the IPHA board of directors since June, 2012, and was appointed to the prescription medicines division strategy board in August, 2012.

Dr Daly joined Janssen in 1998 as head of technical affairs, rising up the ranks to hold a variety of senior positions in medical, sales and marketing, before being appointed to her current position in March, 2012.

Prior to joining Janssen, Dr Daly served at Hoechst Ireland having spent several years in academic clinical research.

25th October 2012

From: Research, Sales, Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics